| Description | U18666A is a cell-permeable drug and is a cholesterol synthesis and transport inhibitor. It inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus. |
| In vitro | U18666A, the antiviral effect is found to result from retarded viral trafficking in the cholesterol-loaded late endosomes/lysosomes and suppressed de novo sterol biosynthesis in treated infected cells. It is also observed an additive antiviral effect of U18666A with C75, a fatty acid synthase inhibitor [1][2]. |
| molecular weight | 424.06 |
| Molecular formula | C25H42ClNO2 |
| CAS | 3039-71-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (117.91 mM), Sonication is recommended. H2O: 10 mg/mL (23.58 mM), Sonication is recommended. |
| References | 1. Poh MK, et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res. 2012 Jan;93(1):191-8. 2. Cenedella RJ, et al. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 2009 Jun;44(6):477-87. |
| Citations | 1. Zhao X, Lian X, Xie J, et al.Accumulated cholesterol protects tumours from elevated lipid peroxidation in the microenvironment.Redox Biology.2023: 102678. 2. Guo Y, Chen Y, Wang Q, et al.Emodin and rhapontigenin inhibit the replication of African swine fever virus by interfering with virus entry.Veterinary Microbiology.2023: 109794. 3. Liu Q, Chen S, Tian R, et al.3β-hydroxysteroid-Δ24 reductase dampens anti-viral innate immune responses by targeting K27 ubiquitination of MAVS and STING.Journal of Virology.2023: e01513-23. |